报价延迟最少15分钟:2026/03/09 20:35 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.76 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.55/1.00
|
|
企业价值
15.29B
|
| 资产负债 |
|
每股账面净值
8.83
|
| 现金流量 |
|
现金流量率
0.23
|
| 损益表 |
|
收益
3.36B
|
|
每股收益
10.17
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA. |
